Year-End Report 18/19

September 2018 – August 2019, Diamyd Medical AB (publ), Fiscal year 2018/2019
To preserve and regain the body’s own insulin production
Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B.
Further information is available on

Figures in parentheses relate to the corresponding period previous financial year.

September 1, 2018 – August 31, 2019

·  Net income: MSEK 1.6 (0.8), whereof the fourth quarter MSEK 0.3 (0.1). The change refers to increased sales of GAD-protein for pre-clinical research.
·  Net result: MSEK –

Source: Year-End Report 18/19

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.